TTM
−$58.88M
YoY change
-28.3%
5Y CAGR
—
Peak year (2012)
−$12.05K
Cumulative net income
−$668.87M
Net Income history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: −$57.39M
Net Income growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -28.3%
Net Income history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | −$57.39M | -28.3% | +$22.59M | ||
| 2024 | −$79.98M | -19.0% | +$18.81M | ||
| 2023 | −$98.79M | -37.1% | +$58.25M | ||
| 2022 | −$157.04M | +24.9% | −$31.29M | ||
| 2021 | −$125.75M | +111.5% | −$66.30M | ||
| 2020 | −$59.46M | +296.2% | −$44.45M | ||
| 2019 | −$15.01M | -13.4% | +$2.31M | ||
| 2018 | −$17.32M | +93.3% | −$8.36M | ||
| 2017 | −$8.96M | +42.5% | −$2.67M | ||
| 2016 | −$6.29M | +111.3% | −$3.31M | ||
| 2015 | −$2.98M | -85.7% | +$17.83M | ||
| 2014 | −$20.80M | +46115.7% | −$20.76M | ||
| 2013 | −$45.02K | +273.5% | −$32.96K | ||
| 2012 | −$12.05K | — | — |
- 2025−$57.39M-28.3%
- 2024−$79.98M-19.0%
- 2023−$98.79M-37.1%
- 2022−$157.04M+24.9%
- 2021−$125.75M+111.5%
- 2020−$59.46M+296.2%
- 2019−$15.01M-13.4%
- 2018−$17.32M+93.3%
- 2017−$8.96M+42.5%
- 2016−$6.29M+111.3%
- 2015−$2.98M-85.7%
- 2014−$20.80M+46115.7%
- 2013−$45.02K+273.5%
- 2012−$12.05K—
Net Income values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current net income (TTM) is −$58.88M. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Relmada Therapeutics (RLMD) most recent annual net income stands at −$57.39M (2025) – declined 28.3% year-over-year.
Across the available history, net income reached its high of −$12.05K in 2012 and its low of −$157.04M in 2022.
Relmada Therapeutics Net Income by Year
Relmada Therapeutics Net Income 2025: −$57.39M
In 2025, Relmada Therapeutics reported net income of −$57.39M, declined 28.3% below 2024.
Relmada Therapeutics Net Income 2024: −$79.98M
Relmada Therapeutics net income in 2024 was −$79.98M, declined 19.0% below 2023.
Relmada Therapeutics Net Income 2023: −$98.79M
2023's net income for Relmada Therapeutics came in at −$98.79M, plunged 37.1% below 2022.
Relmada Therapeutics Net Income 2022: −$157.04M
Relmada Therapeutics posted net income of −$157.04M in 2022, grew 24.9% from 2021. This figure represents the lowest annual value in the available history.
Relmada Therapeutics Net Income 2021: −$125.75M
Relmada Therapeutics net income in 2021 was −$125.75M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Net Income
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation